NEW YORK--(BUSINESS WIRE)--Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4) announced today that through its wholly-owned subsidiary, Synergy Pharmaceuticals, Inc., it initiated oral dosing of healthy volunteers in a Phase I clinical trial of SP-304.
